Genfit stock plummets over 36% in one month with RSI falling to 24
The Lille-based biotech company specializing in hepatic and metabolic diseases continues its correction this Friday morning, consolidating a particularly difficult week that erases a large portion of gains accumulated since the beginning of the year. The publication of half-year results, expected on September 29, approaches in a highly degraded technical context.
A decline settling below all moving averages, RSI in extreme oversold territory
Genfit falls 2.21% to €8.85 in trading, extending a downward movement that has led it to lose nearly 25% over the week and more than 36% in one month. The stock ranks among the strongest declines on the SBF 120 this Friday, in an index nonetheless oriented upward (+0.39%). The technical configuration illustrates the extent of deterioration: the price is trading well below the 20-day moving average (€12.55, gap of -29.5%) and the 50-day moving average (€13.24, gap of -33.2%), two averages that no longer play any reference role in the short term.
The 200-day moving average at €9.40 is the only one that remains within reach, but the price (€8.85) is now also trading below it, at -5.9%. In this picture, the RSI at 24 sinks into extreme oversold territory, reflecting the intensity of selling pressure in recent sessions without indicating an imminent rebound. The MACD also remains in negative territory with a histogram at -0.37, confirming the absence of a trend reversal.
Half-year results on September 29 and a bearish wager establishing itself rapidly
The next concrete milestone for Genfit is set: half-year 2026 results are expected on September 29. The company had posted revenue of €9.6 million in Q1 2026, driven by Iqirvo royalties, with commercial momentum deemed favorable during Q1 2026 publication (May 21, 2026). Dependency on partners for commercial development remains one of the risks highlighted on that occasion. Regarding institutional positioning, consulted disclosures indicate a cumulative net short position of 1.10% of capital, carried by two funds, increasing by 1.10 percentage points over the past thirty days.
This level remains modest in absolute terms, but its rapid progression over the past month, coinciding with the stock's collapse, deserves attention. According to the consensus of surveyed analysts, the stock is currently trading at around 46 times expected earnings for the current fiscal year, versus 10 times those of the following fiscal year, a multiple spread that reflects the still uncertain horizon for profitability. Half-year results on September 29 will provide the next numerical benchmark on the company's financial trajectory.
